<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Calcium-channel blockade impairs renal autoregulation in animals </plain></SENT>
<SENT sid="1" pm="."><plain>Impaired renal autoregulation leads to transmission of the systemic blood pressure (BP) into the glomerulus, resulting in capillary <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Information on the impact of calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> treatment on renal autoregulation in humans is lacking </plain></SENT>
<SENT sid="3" pm="."><plain>This study examines the effect of isradipine treatment on the autoregulation of the glomerular filtration rate (GFR) </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: We performed a randomized double-blind crossover study with 5 mg o.d. isradipine retard and matching placebo in 16 hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Each treatment arm lasted 4 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>On the last day of each treatment period, GFR (single-shot <z:chebi fb="0" ids="50076">51Cr</z:chebi>-EDTA plasma clearance technique for 4 h) was measured twice between 8:00 A.M. and 5:00 P.M., first without <z:chebi fb="4" ids="46631">clonidine</z:chebi> and then after intravenous injection of 75 micro g <z:chebi fb="4" ids="46631">clonidine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>BP was measured every 10 min (Takeda TM2420; A&amp;D, Tokyo) </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:chebi fb="4" ids="46631">Clonidine</z:chebi> reduced mean arterial BP (MABP) by 15 +/- 1 vs. 11 +/- 1 mmHg (means +/- SE) during placebo and isradipine treatment, respectively (P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>GFR was reduced from 102 +/- 4 to 99 +/- 4 ml </plain></SENT>
<SENT sid="10" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="11" pm="."><plain>1.73 m(-2) with placebo (P &lt; 0.01) and from 106 +/- 5 to 98 +/- 5 ml </plain></SENT>
<SENT sid="12" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="13" pm="."><plain>1.73 m(-2) during treatment with isradipine (P &lt; 0.01) </plain></SENT>
<SENT sid="14" pm="."><plain>Mean difference (95% CI) between changes in GFR with placebo and isradipine was -4.6 ml </plain></SENT>
<SENT sid="15" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="16" pm="."><plain>1.73 m(-2) (-10.0 to 0.6) (P = 0.08) </plain></SENT>
<SENT sid="17" pm="."><plain>Six patients had a reduction in GFR &gt;13% (exceeding the <z:mpath ids='MPATH_458'>normal</z:mpath> limit of autoregulation) combined with a complete pressure-passive vasculature (defined as DeltaMABP% &lt; or = DeltaGFR%) during isradipine treatment versus none during the placebo treatment (P &lt; 0.05) </plain></SENT>
<SENT sid="18" pm="."><plain>CONCLUSIONS: Isradipine impairs GFR autoregulation in a sizeable proportion of hypertensive type 2 diabetic patients </plain></SENT>
</text></document>